Sotorasib
|
|
Sotorasib 속성
- 끓는 점
- 730.5±70.0 °C(Predicted)
- 밀도
- 1.36±0.1 g/cm3(Predicted)
- 저장 조건
- Store at -20°C, stored under nitrogen
- 용해도
- DMSO : 100 mg/mL (178.38 mM; Need ultrasonic)|
- 산도 계수 (pKa)
- 6.52±0.35(Predicted)
- 수용성
- Water : 33.33 mg/mL (59.46 mM; ultrasonic and adjust pH to 11 with NaOH)
- InChIKey
- NXQKSXLFSAEQCZ-UHFFFAOYSA-N
- SMILES
- O=C1N=C(N2CCN(C(=O)C=C)CC2C)C2=CC(F)=C(C3C(=CC=CC=3F)O)N=C2N1C1C(=CC=NC=1C(C)C)C
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
| 그림문자(GHS): |
|
|||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 신호 어: | Warning | |||||||||||||||||||||||||||||||||||
| 유해·위험 문구: |
|
|||||||||||||||||||||||||||||||||||
| 예방조치문구: |
|
Sotorasib C화학적 특성, 용도, 생산
일반 설명
Sotorasib, also known as AMG-510, is an acrylamide derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non small cell lung cancer. This mutation makes up >50% of all KRAS mutations. Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s. It is the first experimental KRAS inhibitor. The drug [MRTX849] is also currently being developed and has the same target. Sotorasib was granted FDA approval on 28 May 2021.부작용
Sotorasib may cause breathing problems that could lead to death. Get emergency medical help if you have new or worsening fever, cough, or shortness of breath.Common side effects may include:
nausea, diarrhea;
cough;
liver problems;
pain in your bones, joints, or muscles;
tiredness;
abnormal lab tests.
For 28 patients (22%), side effects led to a pause, a reduction, or both, in the dose of sotorasib. Nine people (7%) stopped the treatment because of side effects.
www.everydayhealth.com/drugs/sotorasib
Mode of action
Sotorasib is an orally available inhibitor of the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets, binds to and inhibits the activity of the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation.Sotorasib 준비 용품 및 원자재
원자재
준비 용품
Sotorasib 공급 업체
글로벌( 182)공급 업체
| 공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
|---|---|---|---|---|---|
| ENBRIDGE PHARMTECH CO., LTD. | +8613812269233 |
tinayang@enbridgepharm.com | China | 303 | 58 |
| Heading （Nanjing）Pharmtechnologies Co., Ltd. | +86-25-58467899-832 +86-13382406280 |
liucheng@headingpharm.com | China | 46 | 58 |
| Tianjin Kilo Pharmaceutical Sci-Tech Co., Ltd | +86-02223869539 +86-15560057295 |
trade.kilopharma@foxmail.com | China | 27 | 58 |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 |
ivan@atkchemical.com | China | 32480 | 60 |
| Jinan Carbotang Biotech Co.,Ltd. | +8615866703830 |
figo.gao@foxmail.com | China | 7019 | 58 |
| CONIER CHEM AND PHARMA LIMITED | +8618523575427 |
sales@conier.com | China | 49390 | 58 |
| Chengdu Aslee Biopharmaceuticals, Inc. | 28-85305008 |
CHINA | 964 | 58 | |
| ANHUI WITOP BIOTECH CO., LTD | +8615255079626 |
eric@witopchemical.com | China | 23556 | 58 |
| Finetech Industry Limited | +86-27-87465837 +8618971612321 |
info@finetechnology-ind.com | China | 9702 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 |
sales@sarms4muscle.com | China | 10523 | 58 |